TOKYO -- Moderna has increased its valuation more than any other drugmaker in the world during the pandemic as new opportunities arising from the coronavirus boost sharp-focused newcomers to new heights.
Markets
Moderna leads all drugmakers in market-cap gain during COVID
Razor focus on cutting-edge technology gives new players an edge
Vials of Moderna's COVID-19 vaccine in Toronto. The company's investment in mRNA technology has paid off handsomely. © Reuters
Read Next
Latest on Markets
